Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Abbott announces availability of HIV treatment in Uganda

Abbott announces availability of HIV treatment in Uganda

3rd December 2007

Abbott has announced that it has made its lower-strength dose of Aluvia (lopinavir/ritonavir) tablet available to children in Uganda living with HIV and Aids.

The company expressed hopes that this move will lead to improvements in the lives of children suffering with the disease, noting that the World Health Organisation recommends the drug for children who are no longer showing a response to first-line treatment for HIV.

Abbott also reports that Aluvia can be taken with or without food and does not require refrigeration, making the drug ideal for patients in the developing world.

The drug is being shipped to Uganda under a waiver signed by the country’s government following the approval of the compound by the US Food and Drug Administration.

Dr Peter Mugyenyi, chair and director of the Joint Clinical Research Centre in Uganda, said: “Introduction of second-line medicine for children living with HIV will help restore hope for millions of parents and children who would otherwise face a bleak future if first-line therapy failed.”

He added that Abbott is making the most novel version of co-formulated lopinavir/ritonavir available to children in poor countries.

Earlier this year, Abbott announced that it would be involved in programmes to increase the scope of HIV testing and treatment in Tanzania.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.